TLRY : Tilray resumed with an outperform rating, Elanco and Shockwave upgraded, and more in today's analyst action • 10:15 AM <br /> <br /> Tilray resumed with an outperform rating <br /> <br /> Following the closing its acquisition with Aphria earlier this month, Cowen has resumed coverage of Tilray (NASDAQ:TLRY) with an outperform rating and $20 price target. <br /> <br /> That implies upside of ~43% from the stock's most recent close. <br /> <br /> Analyst Vivien Azer writes that Tilray is now the market share leader in Canada with "best-in-class profitability." <br /> <br /> She says the company has about a 19% share of the adult cannabis market, ~420 bps above its closest competitor. <br /> <br /> Also, the two companies compliment each other allowing for exposure into different cannabis forms, such as edibles and vaping, as well as into more provinces.